{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T09:19:10Z","timestamp":1766395150984,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99811","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T09:15:32Z","timestamp":1766394932000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Body Mass Index and Hematotoxicity in Gynecological Cancer Patients Receiving Paclitaxel-Carboplatin Therapy: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Teruki","family":"Obana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiko","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Takegami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekatsu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Tsubaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies","volume":"102","author":"Ho GY","year":"2016","unstructured":"Ho GY, Woodward N, Coward JI. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol. 2016, 102:37-46. 10.1016\/j.critrevonc.2016.03.014","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumors: an analysis of the literature","volume":"9","author":"Lokich J","year":"1998","unstructured":"Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998, 9:13-21. 10.1023\/A:1008215213739","journal-title":"Ann Oncol"},{"key":"ref3","article-title":"Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function","volume":"44","author":"Egorin MJ","year":"1984","unstructured":"Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984, 44:5432-8.","journal-title":"Cancer Res"},{"key":"ref4","article-title":"Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function","volume":"44","author":"Harland SJ","year":"1984","unstructured":"Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984, 44:1693-7.","journal-title":"Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert AH","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, et al.. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989, 7:1748-56. 10.1200\/JCO.1989.7.11.1748","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft DW","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16:31-41. 10.1159\/000180580","journal-title":"Nephron"},{"key":"ref7","unstructured":"Follow-up for information letter regarding AUC-based dosing of carboplatin. (2010). Accessed. January 20, 2025: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/memos\/carboplatin-dosing.pdf."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b19-00916","article-title":"Effect of obesity on hematotoxicity induced by carboplatin and paclitaxel combination therapy in patients with gynecological cancer","volume":"43","author":"Ando Y","year":"2020","unstructured":"Ando Y, Hayashi T, Shiouchi H, et al.. Effect of obesity on hematotoxicity induced by carboplatin and paclitaxel combination therapy in patients with gynecological cancer. Biol Pharm Bull. 2020, 43:669-74. 10.1248\/bpb.b19-00916","journal-title":"Biol Pharm Bull"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3119-2","article-title":"Myelosuppression by chemotherapy in obese patients with gynecological cancers","volume":"78","author":"Kamimura K","year":"2016","unstructured":"Kamimura K, Matsumoto Y, Zhou Q, Moriyama M, Saijo Y. Myelosuppression by chemotherapy in obese patients with gynecological cancers. Cancer Chemother Pharmacol. 2016, 78:633-41. 10.1007\/s00280-016-3119-2","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2080-7","article-title":"Hematological toxicity of carboplatin for gynecological cancer according to body mass index","volume":"72","author":"Gutierrez F","year":"2016","unstructured":"Gutierrez F, Gonzalez-de-la-Fuente GA, Nazco GJ, Oramas J, Batista N. Hematological toxicity of carboplatin for gynecological cancer according to body mass index. Eur J Clin Pharmacol. 2016, 72:1083-9. 10.1007\/s00228-016-2080-7","journal-title":"Eur J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2508","article-title":"Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution","volume":"94","author":"Gerchman F","year":"2009","unstructured":"Gerchman F, Tong J, Utzschneider KM, et al.. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. J Clin Endocrinol Metab. 2009, 94:3781-8. 10.1210\/jc.2008-2508","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa R","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T, et al.. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015, 33:2129-35. 10.1200\/JCO.2014.58.4391","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi P","year":"1996","unstructured":"Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996, 49:1373-9. 10.1016\/S0895-4356(96)00236-3","journal-title":"J Clin Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.05.013","article-title":"Carboplatin dosing in the treatment of ovarian cancer: an NRG oncology group study","volume":"174","author":"Praiss AM","year":"2023","unstructured":"Praiss AM, Miller A, Smith J, et al.. Carboplatin dosing in the treatment of ovarian cancer: an NRG oncology group study. Gynecol Oncol. 2023, 174:213-23. 10.1016\/j.ygyno.2023.05.013","journal-title":"Gynecol Oncol"},{"key":"ref15","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). Accessed. November 9, 2025: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01449-3","article-title":"Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study","volume":"24","author":"Bun S","year":"2019","unstructured":"Bun S, Yunokawa M, Ebata T, Kobayashi Kato M, Shimoi T, Kato T, Tamura K. Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study. Int J Clin Oncol. 2019, 24:1111-8. 10.1007\/s10147-019-01449-3","journal-title":"Int J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11548","article-title":"The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel","volume":"98","author":"Hensing TA","year":"2003","unstructured":"Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003, 98:779-88. 10.1002\/cncr.11548","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.03.018","article-title":"The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: an NRG-Oncology\/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study","volume":"173","author":"Sia TY","year":"2023","unstructured":"Sia TY, Tew WP, Purdy C, et al.. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: an NRG-Oncology\/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study. Gynecol Oncol. 2023, 173:130-7. 10.1016\/j.ygyno.2023.03.018","journal-title":"Gynecol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria A","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, et al.. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011, 29:3457-65. 10.1200\/JCO.2011.34.7625","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/IJCTM.S187569","article-title":"Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice","volume":"2018","author":"Bryer E","year":"2018","unstructured":"Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. Int J Clin Transfus Med. 2018, 2018:21-31. 10.2147\/IJCTM.S187569","journal-title":"Int J Clin Transfus Med"},{"key":"ref21","article-title":"Prognostic impact of hemoglobin levels before and during carboplatin\/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer","volume":"15","author":"Eichbaum MH","year":"2009","unstructured":"Eichbaum MH, Weiss LM, Bruckner T, et al.. Prognostic impact of hemoglobin levels before and during carboplatin\/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit. 2009, 15:156-63.","journal-title":"Med Sci Monit"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2426","article-title":"Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group","volume":"16","author":"Gore M","year":"1998","unstructured":"Gore M, Mainwaring P, A'Hern R, et al.. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol. 1998, 16:2426-34. 10.1200\/JCO.1998.16.7.2426","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig H","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, et al.. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004, 40:2293-306. 10.1016\/j.ejca.2004.06.019","journal-title":"Eur J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.07.093","article-title":"Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study","volume":"123","author":"Phippen NT","year":"2011","unstructured":"Phippen NT, Lowery WJ, Barnett JC, Hall LA, Landt C, Leath CA 3rd. Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study. Gynecol Oncol. 2011, 123:360-4. 10.1016\/j.ygyno.2011.07.093","journal-title":"Gynecol Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5649\/JJPHCS.41.759","article-title":"Survey on the usage of the Calvert formula to calculate AUC-based carboplatin dosing in Japan [Article in Japanese]","volume":"41","author":"Imamura C","year":"2015","unstructured":"Imamura C, Kato Y, Shimokata T, Ando Y, Tanigawara Y. Survey on the usage of the Calvert formula to calculate AUC-based carboplatin dosing in Japan [Article in Japanese]. Jpn J Pharm Health Care Sci. 2015, 41:759-67. 10.5649\/JJPHCS.41.759","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110560","article-title":"Impact of a new assay for measuring serum creatinine levels on carboplatin dosing","volume":"69","author":"Murray B","year":"2012","unstructured":"Murray B, Bates J, Buie L. Impact of a new assay for measuring serum creatinine levels on carboplatin dosing. Am J Health Syst Pharm. 2012, 69:1136-41. 10.2146\/ajhp110560","journal-title":"Am J Health Syst Pharm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs JJ","year":"2012","unstructured":"Griggs JJ, Mangu PB, Anderson H, et al.. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012, 30:1553-61. 10.1200\/JCO.2011.39.9436","journal-title":"J Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm606","article-title":"Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial","volume":"19","author":"Barrett SV","year":"2008","unstructured":"Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol. 2008, 19:898-902. 10.1093\/annonc\/mdm606","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3865","article-title":"Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer","volume":"10","author":"Gota V","year":"2021","unstructured":"Gota V, Nookala M, Bonda A, et al.. Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer. Cancer Med. 2021, 10:3068-76. 10.1002\/cam4.3865","journal-title":"Cancer Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.233","article-title":"Acute and cumulative effects of carboplatin on renal function","volume":"60","author":"Sleijfer DT","year":"1989","unstructured":"Sleijfer DT, Smit EF, Meijer S, Mulder NH, Postmus PE. Acute and cumulative effects of carboplatin on renal function. Br J Cancer. 1989, 60:116-20. 10.1038\/bjc.1989.233","journal-title":"Br J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437842-association-between-body-mass-index-and-hematotoxicity-in-gynecological-cancer-patients-receiving-paclitaxel-carboplatin-therapy-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T09:15:33Z","timestamp":1766394933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437842-association-between-body-mass-index-and-hematotoxicity-in-gynecological-cancer-patients-receiving-paclitaxel-carboplatin-therapy-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.99811","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}